Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sonnet BioTherapeutics Holdings ( (SONN) ) has issued an announcement.
On May 30, 2025, Sonnet BioTherapeutics Holdings received a deficiency notice from Nasdaq for not meeting the $2.5 million minimum stockholders’ equity requirement. By July 15, 2025, the company secured approximately $5.5 million from a private placement offering and an additional $10.5 million from warrant exercises, potentially bringing it back into compliance, pending Nasdaq’s confirmation.
The most recent analyst rating on (SONN) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Sonnet BioTherapeutics Holdings stock, see the SONN Stock Forecast page.
Spark’s Take on SONN Stock
According to Spark, TipRanks’ AI Analyst, SONN is a Neutral.
Sonnet BioTherapeutics Holdings presents a high-risk investment profile due to severe financial instability, including negative equity and ongoing losses. Technical analysis offers some potential for price appreciation, but the high RSI indicates a risk of overbought conditions. The proposed merger could offer a transformative opportunity, but the company’s Nasdaq non-compliance poses a significant risk. Investors should exercise caution given the combination of these factors.
To see Spark’s full report on SONN stock, click here.
More about Sonnet BioTherapeutics Holdings
Sonnet BioTherapeutics Holdings operates in the biotechnology industry, focusing on developing innovative biotherapeutic products.
Average Trading Volume: 3,753,358
Technical Sentiment Signal: Hold
Current Market Cap: $28.69M
Learn more about SONN stock on TipRanks’ Stock Analysis page.